HEC585 dose A

Phase 2

PharmaMar, S.A. (PHM.MC)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

PHM.MCPhase 2$1.4B

HEC585 dose A Phase 2 Est. Readout

HEC585 dose A• Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)110

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)

View Full Landscape

Drug Information

Target Indication

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)

Clinical Trial

NCT05139719

Last updated: 9/30/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

PHM.MC

PharmaMar, S.A.

Operative Builders•Europe•BME

Related Pipeline

ChronocortPhase 3

Congenital Adrenal Hyperplasia

TryptophanPhase 3

Schizophrenia

hCRFPhase 3

Brain Edema

Eslicarbazepine acetate 1600 mgPhase 3

Epilepsy

LevalbuterolPhase 3

Asthma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts